I just started working on the complementary side of the spike RBD-ACE2 interaction, making an aerosol of RBD peptide fragments to outcompete the virus for entry

I just started working on the complementary side of the spike RBD-ACE2 interaction, making an aerosol of RBD peptide fragments to outcompete the virus for entry. This work is based on B-cell epitope mapping of SARS patients and subsequent identification of ACE2 binding peptides like: https://www.sciencedirect.com/science/article/pii/S0166354211005481 https://www.sciencedirect.com/science/article/pii/S016635421... I'm the "dry lab" side of this project -- looking for peptide candidates. My other collaborators at UNC are going to do formulate the aerosol and test for safety in mice. Normally this would be a very early stage in drug development, but it seems like we have to move quickly. So similar shout out to the Gates Foundation folks -- if you're interested in this approach email alex.rubinsteyn@unc.edu